Congenital muscular dystrophy (CMD) is a group of inherited muscle diseases that cause weakness and low muscle tone at birth or within the first few months of life. Unlike other forms of muscular dystrophy that appear in childhood or adolescence, CMD is present from the very beginning. It encompasses more than 30 subtypes, each linked to a different genetic mutation, and the severity ranges widely, from children who eventually walk independently to those who need lifelong breathing support.
How CMD Appears in Infants
The hallmark of congenital muscular dystrophy is muscle weakness that’s noticeable at or shortly after birth. In newborns, this often looks like poor muscle tone, sometimes called “floppy infant syndrome.” A baby with CMD may make very few spontaneous arm or leg movements, have a weak cry, and struggle to feed because the muscles involved in sucking are too weak. Joint contractures, where muscles and ligaments around a joint become tight and limit its range of motion, can also be present at birth or develop over time.
As children grow, additional issues may surface depending on the subtype. Some children develop scoliosis (curvature of the spine), pressure ulcers from limited mobility, and respiratory problems as the muscles that support breathing gradually weaken. In certain subtypes, the brain and eyes are also affected, leading to intellectual disability, seizures, or vision problems. In other subtypes, cognition is completely normal and weakness stays relatively mild.
What Causes It
CMD is caused by mutations in genes that produce proteins essential for muscle cell structure and stability. Healthy muscle cells depend on a network of proteins that anchor the interior of the cell to the surrounding tissue. When one of these proteins is missing, malformed, or produced in insufficient quantities, the muscle cell membrane becomes fragile. Over time, the cells leak their internal contents, break down, and die. The body replaces dead muscle fibers with fat and scar tissue rather than new muscle, which is why weakness is progressive.
Different CMD subtypes involve different proteins. Some mutations affect proteins in the outer scaffold that connects muscle cells to the tissue around them, while others disrupt proteins that help muscle cells communicate with the brain during fetal development. This is why some subtypes cause only muscle problems while others also affect brain structure.
CMD is almost always inherited in an autosomal recessive pattern, meaning a child must receive a copy of the mutated gene from each parent. Parents who carry one copy typically have no symptoms themselves. In rare cases, CMD can result from a new (de novo) mutation that wasn’t inherited from either parent.
Major Subtypes
Though there are dozens of CMD subtypes, a few are more common and well-studied than the rest.
Merosin-Deficient CMD (MDC1A)
This is one of the most common forms in Western countries. It’s caused by mutations in the LAMA2 gene, which produces a protein called laminin-211 (also known as merosin) that normally anchors muscle cells to the surrounding tissue. Children with MDC1A typically have severe weakness and rarely achieve independent walking. Brain MRI scans often show abnormal white matter signals, though intelligence is usually normal. Respiratory weakness tends to be a significant concern and often requires nighttime ventilation support.
Ullrich CMD
Caused by mutations affecting collagen VI, Ullrich CMD produces a distinctive combination: proximal joint contractures (tight hips, knees, and elbows) alongside unusual looseness in the hands, wrists, and ankles. Children may initially gain some ability to walk but often lose it by adolescence. Respiratory decline is common and tends to progress even when limb strength is relatively stable, making breathing support an important part of ongoing care.
Fukuyama CMD
Most common in Japan, this subtype is caused by a mutation in the fukutin gene. It affects both muscles and brain development, leading to significant intellectual disability, seizures, and eye abnormalities alongside severe muscle weakness. Most children with Fukuyama CMD do not walk independently. Life expectancy is typically shortened, with respiratory and cardiac complications being the primary concerns.
Alpha-Dystroglycanopathies
This group includes several subtypes (Walker-Warburg syndrome, muscle-eye-brain disease, and others) that share a common problem: faulty chemical modification of a protein called alpha-dystroglycan. These conditions often affect the brain and eyes in addition to muscle, and severity varies enormously. Walker-Warburg syndrome is the most severe form, with profound brain malformations, while milder variants may cause only moderate weakness with subtle or no brain involvement.
How CMD Is Diagnosed
Diagnosis usually begins when a newborn or young infant shows unexplained low muscle tone and weakness. The process involves ruling out other causes, particularly spinal muscular atrophy (SMA), which can look very similar in infants but has a different underlying mechanism. One useful early distinction is a blood test for creatine kinase (CK), an enzyme that leaks out of damaged muscle cells. CK levels are often elevated in CMD but typically normal in SMA, because SMA damages the nerve cells that control muscles rather than the muscles themselves.
Brain MRI is an important part of the workup because certain CMD subtypes produce characteristic patterns of brain abnormality, even when a child’s thinking and development seem normal. White matter changes on MRI, for example, are a strong clue pointing toward merosin-deficient CMD.
Genetic testing has become the cornerstone of CMD diagnosis. Whole-exome or targeted gene panel sequencing can identify the specific mutation responsible, which matters because the subtype determines prognosis, management priorities, and genetic counseling for the family. Muscle biopsy, once the standard diagnostic tool, is now used less frequently but can still help when genetic testing is inconclusive. Under the microscope, CMD muscle tissue shows characteristic signs of dystrophy: variation in fiber size, dead and regenerating fibers, and replacement of muscle with fat and connective tissue.
Treatment and Daily Management
There is currently no cure for any form of CMD. Treatment focuses on preserving function, preventing complications, and supporting quality of life through a team-based approach involving physical therapists, occupational therapists, speech therapists, pulmonologists, orthopedic specialists, and neurologists.
Physical and Occupational Therapy
Range-of-motion exercises are a mainstay of care, aimed at keeping joints flexible and slowing the progression of contractures. Braces and orthotic devices are commonly used for the same purpose, though evidence for their long-term effectiveness is limited. For children who develop tight heel cords or other fixed contractures, surgical lengthening procedures can provide at least short-term relief. Seating specialists and mobility equipment (adaptive strollers, power wheelchairs) become important as children grow, helping them participate in school and social life.
Respiratory Monitoring
Breathing problems are one of the most serious complications of CMD, and they can develop quietly. A child’s breathing may seem fine during the day while oxygen levels drop significantly during sleep. Regular monitoring of lung function and overnight oxygen levels is standard practice, with the frequency tailored to each child’s clinical status. Many children with moderate to severe CMD eventually benefit from nighttime ventilation support, often through a mask rather than an invasive procedure.
Nutrition and Feeding
Weak oral muscles can make eating slow, tiring, and sometimes unsafe if food enters the airway. Speech therapists assess swallowing function and recommend texture modifications or feeding strategies. Some children need supplemental tube feeding to maintain adequate nutrition, particularly during growth spurts or illness.
Scoliosis Management
Progressive spinal curvature is common in children with CMD who have limited trunk strength. Spinal fusion surgery can correct the curve and prevent further progression, improving sitting posture and balance. Studies have shown stable results over at least two years following surgery, though the impact on breathing function is less clear. The decision about surgery involves weighing the benefits of spinal stability against surgical risks in a child who may already have compromised respiratory function.
Prognosis and Long-Term Outlook
The outlook for CMD varies dramatically by subtype and even within the same subtype. Some children with milder forms (such as certain collagen VI-related or alpha-dystroglycanopathy variants) achieve independent walking and maintain it well into adulthood. Others, particularly those with merosin-deficient CMD or severe brain-involved subtypes, face more significant physical limitations from early in life.
Respiratory complications are the leading cause of shortened life expectancy across most CMD subtypes. Proactive respiratory monitoring and early intervention with ventilation support have improved survival significantly over the past two decades. Many people with CMD now live into adulthood, and the trajectory continues to improve as care standards evolve. The specific genetic diagnosis matters enormously for families trying to understand what to expect, which is one reason confirming the exact subtype through genetic testing is so valuable.
Research in Progress
Several lines of active research are targeting specific CMD subtypes. Gene therapy approaches are being explored for merosin-deficient CMD, with investigators working on ways to modulate the genes involved in laminin-211 production. CRISPR gene-editing technology is being studied for its potential to correct cardiac abnormalities in CMD caused by LMNA mutations. Other research teams are screening existing drugs for potential repurposing, looking for compounds that might protect muscle cells from the downstream effects of missing or dysfunctional proteins. These efforts are still in preclinical or early-phase stages, but they represent the first time targeted molecular therapies have been seriously pursued for congenital muscular dystrophy.